The management of patients with oligometastatic urothelial carcinoma (UC) represents an evolving field in uro-oncology, and the role of metastasis-directed therapies, including metastasectomy and metastasis-directed radiation therapy (MDRT), is gaining increasing attention. Herein, we summarize available evidence about the role of MDRT with consolidative intent in oligometastatic UC patients. A systematic review was performed in December 2021. Six studies involving 158 patients were identified. Most patients (n = 120, 90.2%) had a history of bladder cancer and the most frequent sites of metastases were lymph nodes (n = 61, 52.1%) followed by the lungs (n = 34, 29%). Overall, 144 metastases were treated with MDRT. Median follow-up ranged from 17.2 to 25 months. Local control rates ranged from 57% to 100%. Median Overall Survival (OS) ranged from 14.9 to 51.0 months and median progression-free survival ranged from 2.9 to 10.1 months. Rates of OS at one and two years ranged from 78.9% to 96% and from 26% to 63%, respectively. Treatment-related toxicity was recorded in few patients and in most cases a low-grade toxicity was evident. MDRT with consolidative intent represents a potential treatment option for selected patients with oligometastatic UC.
Metastasis-Directed Radiation Therapy with Consolidative Intent for Oligometastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis / Longo, Nicola; Celentano, Giuseppe; Napolitano, Luigi; La Rocca, Roberto; Capece, Marco; Califano, Gianluigi; Collà Ruvolo, Claudia; Mangiapia, Francesco; Fusco, Ferdinando; Morra, Simone; Turco, Carmine; Di Bello, Francesco; Fusco, Giovanni Maria; Cirillo, Luigi; Cacciapuoti, Crescenzo; Spirito, Lorenzo; Calogero, Armando; Sica, Antonello; Sagnelli, Caterina; Creta, Massimiliano. - In: CANCERS. - ISSN 2072-6694. - 14:10(2022), p. 2373. [10.3390/cancers14102373]
Metastasis-Directed Radiation Therapy with Consolidative Intent for Oligometastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
Longo, Nicola;Celentano, Giuseppe;Napolitano, Luigi
;La Rocca, Roberto;Capece, Marco;Califano, Gianluigi;Collà Ruvolo, Claudia;Mangiapia, Francesco;Morra, Simone;Turco, Carmine;Di Bello, Francesco;Fusco, Giovanni Maria;Cirillo, Luigi;Cacciapuoti, Crescenzo;Spirito, Lorenzo;Calogero, Armando;Creta, MassimilianoUltimo
2022
Abstract
The management of patients with oligometastatic urothelial carcinoma (UC) represents an evolving field in uro-oncology, and the role of metastasis-directed therapies, including metastasectomy and metastasis-directed radiation therapy (MDRT), is gaining increasing attention. Herein, we summarize available evidence about the role of MDRT with consolidative intent in oligometastatic UC patients. A systematic review was performed in December 2021. Six studies involving 158 patients were identified. Most patients (n = 120, 90.2%) had a history of bladder cancer and the most frequent sites of metastases were lymph nodes (n = 61, 52.1%) followed by the lungs (n = 34, 29%). Overall, 144 metastases were treated with MDRT. Median follow-up ranged from 17.2 to 25 months. Local control rates ranged from 57% to 100%. Median Overall Survival (OS) ranged from 14.9 to 51.0 months and median progression-free survival ranged from 2.9 to 10.1 months. Rates of OS at one and two years ranged from 78.9% to 96% and from 26% to 63%, respectively. Treatment-related toxicity was recorded in few patients and in most cases a low-grade toxicity was evident. MDRT with consolidative intent represents a potential treatment option for selected patients with oligometastatic UC.File | Dimensione | Formato | |
---|---|---|---|
cancers-14-02373.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Dominio pubblico
Dimensione
7.87 MB
Formato
Adobe PDF
|
7.87 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.